Nicolai Thomsen - Ambu A/S Director Planning
| AMBFF Stock | USD 19.90 0.00 0.00% |
Insider
Nicolai Thomsen is Director Planning of Ambu AS
| Phone | 45 72 25 20 00 |
| Web | https://www.ambu.com |
Ambu A/S Management Efficiency
The company has return on total asset (ROA) of 0.0141 % which means that it generated a profit of $0.0141 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0236 %, meaning that it generated $0.0236 on every $100 dollars invested by stockholders. Ambu A/S's management efficiency ratios could be used to measure how well Ambu A/S manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Steven Payne | Globus Medical | 53 | |
| Donald Middlebrook | Nevro Corp | 69 | |
| Pr MD | Novocure | 86 | |
| William Burke | Novocure | 69 | |
| Ashley Cordova | Novocure | 45 | |
| Ajit Ramalingam | Bio Rad Laboratories | 51 | |
| Karen Prange | Nevro Corp | 56 | |
| Uri MD | Novocure | 45 | |
| Richard Holifield | Globus Medical | N/A | |
| Sridhar Kosaraju | Nevro Corp | 42 | |
| Simon May | Bio Rad Laboratories | 52 | |
| Mike Reeder | Globus Medical | N/A | |
| Lauren Budden | Insulet | 49 | |
| Michael Carter | Nevro Corp | 52 | |
| Richard Carter | Nevro Corp | 53 | |
| Stephen Zarrilli | Globus Medical | 58 | |
| Robert Douglas | Globus Medical | 60 | |
| Kelly Huller | Globus Medical | 48 | |
| Julie Dewey | Nevro Corp | 63 | |
| Dara Wright | Bio Rad Laboratories | 48 | |
| Ingrid Goldberg | Novocure | N/A | |
Management Performance
| Return On Equity | 0.0236 | |||
| Return On Asset | 0.0141 |
Ambu A/S Leadership Team
Elected by the shareholders, the Ambu A/S's board of directors comprises two types of representatives: Ambu A/S inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ambu. The board's role is to monitor Ambu A/S's management team and ensure that shareholders' interests are well served. Ambu A/S's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ambu A/S's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Schmidt, Ex CFO | ||
| Henrik Ankjr, Ex Operations | ||
| Thomas Henriksen, Director, Employee Representative | ||
| Anders Williamsson, Managing Director | ||
| Steven Block, CEO USA | ||
| Nicolai Thomsen, Director Planning | ||
| Mikkel Wagner, Director Communications | ||
| Bassel Rifai, Chief VP | ||
| Mns Barsne, Ex Officer | ||
| Britt Jensen, Chief Officer |
Ambu Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Ambu A/S a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0236 | |||
| Return On Asset | 0.0141 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.03 % | |||
| Current Valuation | 3.73 B | |||
| Shares Outstanding | 219.75 M | |||
| Shares Owned By Insiders | 26.04 % | |||
| Shares Owned By Institutions | 36.20 % | |||
| Price To Earning | 64.15 X | |||
| Price To Book | 5.10 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Ambu Pink Sheet
Ambu A/S financial ratios help investors to determine whether Ambu Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ambu with respect to the benefits of owning Ambu A/S security.